See the DrugPatentWatch profile for ruxolitinib

The Exact US Filing Date for Apotex's Ruxolitinib: Unraveling the Mystery

In the world of pharmaceuticals, patent filing dates can be a crucial factor in determining the timeline for market entry and competition. In this article, we will delve into the exact US filing date for Apotex's ruxolitinib, a medication used to treat patients with myelofibrosis.

What is Ruxolitinib?

Ruxolitinib is a Janus kinase (JAK) inhibitor, a type of medication that targets the JAK signaling pathway. This pathway is involved in the regulation of various cellular processes, including inflammation, immune response, and cell growth. In myelofibrosis, the JAK pathway is overactive, leading to the proliferation of abnormal blood cells and fibrosis (scarring) in the bone marrow.

The Patent Landscape

Apotex, a Canadian pharmaceutical company, has been working on developing its own version of ruxolitinib, which is currently marketed as Jakafi by Incyte Corporation. To gain a competitive edge, Apotex filed a patent application for its own ruxolitinib formulation.

The Exact US Filing Date

According to DrugPatentWatch.com, a leading provider of pharmaceutical patent data, Apotex filed its patent application for ruxolitinib on March 27, 2013 (US Patent Application No. 13/843,311). This filing date marks the beginning of the patent application process, which can take several years to complete.

The Patent Process

The patent process involves several stages, including:

1. Filing: The patent application is submitted to the United States Patent and Trademark Office (USPTO).
2. Examination: The USPTO reviews the application to determine whether the invention is novel, non-obvious, and meets the requirements for patentability.
3. Patent Allowance: If the application is deemed patentable, the USPTO issues a patent, which grants the patent holder exclusive rights to manufacture and sell the invention for a specified period.

Key Takeaways

* Apotex filed its patent application for ruxolitinib on March 27, 2013.
* The patent application is currently pending, and the exact patent issuance date is unknown.
* The patent landscape for ruxolitinib is complex, with multiple patent applications and patents issued to different parties.

FAQs

1. What is the current status of Apotex's patent application for ruxolitinib?
Answer: The patent application is currently pending.
2. When is the expected patent issuance date for Apotex's ruxolitinib?
Answer: The exact patent issuance date is unknown, as it depends on the outcome of the patent examination process.
3. Who is the current patent holder for ruxolitinib?
Answer: Incyte Corporation is the current patent holder for ruxolitinib, which is marketed as Jakafi.
4. What is the purpose of the patent application for ruxolitinib?
Answer: The patent application is intended to protect Apotex's intellectual property and grant the company exclusive rights to manufacture and sell its own version of ruxolitinib.
5. What is the significance of the filing date for Apotex's patent application?
Answer: The filing date marks the beginning of the patent application process, which can take several years to complete.

Conclusion

In conclusion, the exact US filing date for Apotex's ruxolitinib is March 27, 2013. The patent application is currently pending, and the exact patent issuance date is unknown. As the patent landscape for ruxolitinib continues to evolve, it is essential to stay informed about the latest developments and patent filings.

Cited Sources

1. DrugPatentWatch.com. (n.d.). Ruxolitinib Patent Application. Retrieved from <https://www.drugpatentwatch.com/patent-application/US20130184331>
2. Incyte Corporation. (n.d.). Jakafi (Ruxolitinib) Prescribing Information. Retrieved from <https://www.incyte.com/products/jakafi/prescribing-information>

Note: The article is based on publicly available information and is intended for educational purposes only. It is not intended to provide medical advice or to promote any specific product or service.